THE GIBSON GROUP, LLC for ENDO PHARMACEUTICALS INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues relating to incentives for life sciences research. H.R. 523/S. 232: Protect Medical Innovation Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON | — |
Copyright/Patent/Trademark CPT
Oversight of implementation of the America Invents Act. Issues relating to patent settlements, including S. 214: Preserve Access to Affordable Generics Act. H.R. 3309: Innovation Act. S. 1720: Patent Transparency and Improvements Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON | — |
Health Issues HCR
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. Compounding and drug supply chain legislation. H.R. 3204: Drug Quality and Security Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON | Counsel, House Judiciary Comm. '95-'97 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.